目次

Table of Contents

Chapter 1. Methodology And Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Therapy
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Market Variables, Trends, & Scope
2.1. Market Segmentation and Scope
2.2. Market Lineage Outlook
2.2.1. Parent Market Outlook
2.2.2. Related/Ancillary Market Outlook
2.3. Market Trends and Outlook
2.4. Market Dynamics
2.4.1. Advances in Immunotherapy and Targeted Therapies
2.4.2. Increasing Prevalence of T-cell Lymphoma Globally
2.4.3. Regulatory Approvals and Expanded Indications for Novel Treatments
2.5. Market Restraint Analysis
2.5.1. High Cost of Innovative Therapies
2.5.2. Limited Awareness and Diagnosis in Developing Regions
2.6. Business Environment Analysis
2.6.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
2.6.2. Porter’s Five Forces Analysis
2.7. COVID-19 Impact Analysis

Chapter 3. T-cell Lymphoma Market: Type Business Analysis
3.1. Type Market Share, 2023 & 2030
3.2. Segment Dashboard
3.3. T-cell Lymphomas Market by Type Outlook
3.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
3.5. Peripheral
3.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
3.5.2. Cutaneous T-cell Lymphoma
3.5.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
3.5.3. Anaplastic Large Cell Lymphoma
3.5.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
3.5.4. Angio-immuno-blastic T-cell Lymphoma
3.5.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
3.5.5. Other
3.5.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
3.6. Lymphoblastic
3.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 4. T-cell Lymphoma Market: Therapy Business Analysis
4.1. Therapy Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. T-cell Lymphomas Market by Therapy Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Radiotherapy
4.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Chemotherapy
4.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Immunotherapy
4.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Stem Cell Transplantation
4.8.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.9. Other
4.9.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. T-cell Lymphoma Market: Regional Business Analysis
5.1. T-cell Lymphoma Market Share By Region, 2023 & 2030
5.2. North America
5.2.1. U.S.
5.2.1.1. Key Country Dynamics
5.2.1.2. Target Disease Prevalence
5.2.1.3. Competitive Scenario
5.2.1.4. Regulatory Framework
5.2.1.5. Reimbursement Scenario
5.2.1.6. U.S. T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.2.2. Canada
5.2.2.1. Key Country Dynamics
5.2.2.2. Target Disease Prevalence
5.2.2.3. Competitive Scenario
5.2.2.4. Regulatory Framework
5.2.2.5. Reimbursement Scenario
5.2.2.6. Canada T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.2.3. Mexico
5.2.3.1. Key Country Dynamics
5.2.3.2. Target Disease Prevalence
5.2.3.3. Competitive Scenario
5.2.3.4. Regulatory Framework
5.2.3.5. Reimbursement Scenario
5.2.3.6. Mexico T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.3. Europe
5.3.1. Europe T-cell Lymphomas Market, 2018 - 2030 (USD Million)
5.3.2. Germany
5.3.2.1. Key Country Dynamics
5.3.2.2. Target Disease Prevalence
5.3.2.3. Competitive Scenario
5.3.2.4. Regulatory Framework
5.3.2.5. Reimbursement Scenario
5.3.2.6. Germany T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.3.3. UK
5.3.3.1. Key Country Dynamics
5.3.3.2. Target Disease Prevalence
5.3.3.3. Competitive Scenario
5.3.3.4. Regulatory Framework
5.3.3.5. Reimbursement Scenario
5.3.3.6. UK T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.3.4. France
5.3.4.1. Key Country Dynamics
5.3.4.2. Target Disease Prevalence
5.3.4.3. Competitive Scenario
5.3.4.4. Regulatory Framework
5.3.4.5. Reimbursement Scenario
5.3.4.6. France T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.3.5. Italy
5.3.5.1. Key Country Dynamics
5.3.5.2. Target Disease Prevalence
5.3.5.3. Competitive Scenario
5.3.5.4. Regulatory Framework
5.3.5.5. Reimbursement Scenario
5.3.5.6. Italy T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.3.6. Spain
5.3.6.1. Key Country Dynamics
5.3.6.2. Target Disease Prevalence
5.3.6.3. Competitive Scenario
5.3.6.4. Regulatory Framework
5.3.6.5. Reimbursement Scenario
5.3.6.6. Spain T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.3.7. Denmark
5.3.7.1. Key Country Dynamics
5.3.7.2. Target Disease Prevalence
5.3.7.3. Competitive Scenario
5.3.7.4. Regulatory Framework
5.3.7.5. Reimbursement Scenario
5.3.7.6. Denmark T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.3.8. Sweden
5.3.8.1. Key Country Dynamics
5.3.8.2. Target Disease Prevalence
5.3.8.3. Competitive Scenario
5.3.8.4. Regulatory Framework
5.3.8.5. Reimbursement Scenario
5.3.8.6. Sweden T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.3.9. Norway
5.3.9.1. Key Country Dynamics
5.3.9.2. Target Disease Prevalence
5.3.9.3. Competitive Scenario
5.3.9.4. Regulatory Framework
5.3.9.5. Reimbursement Scenario
5.3.9.6. Norway T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.4. Asia Pacific
5.4.1. Asia Pacific T-cell Lymphoma Market,, 2018 - 2030 (USD Million)
5.4.2. Japan
5.4.2.1. Key Country Dynamics
5.4.2.2. Target Disease Prevalence
5.4.2.3. Competitive Scenario
5.4.2.4. Regulatory Framework
5.4.2.5. Reimbursement Scenario
5.4.2.6. Japan T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.4.3. China
5.4.3.1. Key Country Dynamics
5.4.3.2. Target Disease Prevalence
5.4.3.3. Competitive Scenario
5.4.3.4. Regulatory Framework
5.4.3.5. Reimbursement Scenario
5.4.3.6. China T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.4.4. India
5.4.4.1. Key Country Dynamics
5.4.4.2. Target Disease Prevalence
5.4.4.3. Competitive Scenario
5.4.4.4. Regulatory Framework
5.4.4.5. Reimbursement Scenario
5.4.4.6. India T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.4.5. South Korea
5.4.5.1. Key Country Dynamics
5.4.5.2. Target Disease Prevalence
5.4.5.3. Competitive Scenario
5.4.5.4. Regulatory Framework
5.4.5.5. Reimbursement Scenario
5.4.5.6. South Korea T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.4.6. Australia
5.4.6.1. Key Country Dynamics
5.4.6.2. Target Disease Prevalence
5.4.6.3. Competitive Scenario
5.4.6.4. Regulatory Framework
5.4.6.5. Reimbursement Scenario
5.4.6.6. Australia T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.4.7. Thailand
5.4.7.1. Key Country Dynamics
5.4.7.2. Target Disease Prevalence
5.4.7.3. Competitive Scenario
5.4.7.4. Regulatory Framework
5.4.7.5. Reimbursement Scenario
5.4.7.6. Thailand T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.5. Latin America
5.5.1. Latin America T-cell Lymphoma Market,, 2018 - 2030 (USD Million)
5.5.2. Brazil
5.5.2.1. Key Country Dynamics
5.5.2.2. Target Disease Prevalence
5.5.2.3. Competitive Scenario
5.5.2.4. Regulatory Framework
5.5.2.5. Reimbursement Scenario
5.5.2.6. Brazil T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.5.3. Argentina
5.5.3.1. Key Country Dynamics
5.5.3.2. Target Disease Prevalence
5.5.3.3. Competitive Scenario
5.5.3.4. Regulatory Framework
5.5.3.5. Reimbursement Scenario
5.5.3.6. Argentina T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.6. MEA
5.6.1. MEA T-cell Lymphoma Market,, 2018 - 2030 (USD Million)
5.6.2. South Africa
5.6.2.1. Key Country Dynamics
5.6.2.2. Target Disease Prevalence
5.6.2.3. Competitive Scenario
5.6.2.4. Regulatory Framework
5.6.2.5. Reimbursement Scenario
5.6.2.6. South Africa T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.6.3. Saudi Arabia
5.6.3.1. Key Country Dynamics
5.6.3.2. Target Disease Prevalence
5.6.3.3. Competitive Scenario
5.6.3.4. Regulatory Framework
5.6.3.5. Reimbursement Scenario
5.6.3.6. Saudi Arabia T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.6.4. UAE
5.6.4.1. Key Country Dynamics
5.6.4.2. Target Disease Prevalence
5.6.4.3. Competitive Scenario
5.6.4.4. Regulatory Framework
5.6.4.5. Reimbursement Scenario
5.6.4.6. UAE T-cell Lymphoma Market, 2018 - 2030 (USD Million)
5.6.5. Kuwait
5.6.5.1. Key Country Dynamics
5.6.5.2. Target Disease Prevalence
5.6.5.3. Competitive Scenario
5.6.5.4. Regulatory Framework
5.6.5.5. Reimbursement Scenario
5.6.5.6. Kuwait T-cell Lymphoma Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape
6.1. Participant’s overview
6.2. Financial performance
6.3. Participant categorization
6.3.1. Market Leaders
6.3.2. T-cell Lymphoma Market Share Analysis, 2023
6.3.3. Company Profiles
6.3.3.1. Acrotech Biopharma
6.3.3.1.1. Company Overview
6.3.3.1.2. Financial Performance
6.3.3.1.3. Product Benchmarking
6.3.3.1.4. Strategic Initiatives
6.3.3.2. Affimed GmbH
6.3.3.2.1. Company Overview
6.3.3.2.2. Financial Performance
6.3.3.2.3. Product Benchmarking
6.3.3.2.4. Strategic Initiatives
6.3.3.3. Bristol Myers Squibb
6.3.3.3.1. Company Overview
6.3.3.3.2. Financial Performance
6.3.3.3.3. Product Benchmarking
6.3.3.3.4. Strategic Initiatives
6.3.3.4. Chipscreen Biosciences
6.3.3.4.1. Company Overview
6.3.3.4.2. Financial Performance
6.3.3.4.3. Product Benchmarking
6.3.3.4.4. Strategic Initiatives
6.3.3.5. Citius Pharma
6.3.3.5.1. Company Overview
6.3.3.5.2. Financial Performance
6.3.3.5.3. Product Benchmarking
6.3.3.5.4. Strategic Initiatives
6.3.3.6. DAIICHI SANKYO COMPANY, LIMITED
6.3.3.6.1. Company Overview
6.3.3.6.2. Financial Performance
6.3.3.6.3. Product Benchmarking
6.3.3.6.4. Strategic Initiatives
6.3.3.7. Eisai Co., Ltd.
6.3.3.7.1. Company Overview
6.3.3.7.2. Financial Performance
6.3.3.7.3. Product Benchmarking
6.3.3.7.4. Strategic Initiatives
6.3.3.8. Genor Biopharma Co. Ltd
6.3.3.8.1. Company Overview
6.3.3.8.2. Financial Performance
6.3.3.8.3. Product Benchmarking
6.3.3.8.4. Strategic Initiatives
6.3.3.9. Innate Pharma
6.3.3.9.1. Company Overview
6.3.3.9.2. Financial Performance
6.3.3.9.3. Product Benchmarking
6.3.3.9.4. Strategic Initiatives
6.3.3.10. Dizal Pharma
6.3.3.10.1. Company Overview
6.3.3.10.2. Financial Performance
6.3.3.10.3. Product Benchmarking
6.3.3.10.4. Strategic Initiatives
6.3.4. Strategy Mapping
6.3.4.1. Expansion
6.3.4.2. Acquisition
6.3.4.3. Collaborations
6.3.4.4. Product/Service Launch
6.3.4.5. Partnerships
6.3.4.6. Others

List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global T-cell Lymphoma Market, by Region, 2018 - 2030 (USD Million)
Table 4 Global T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 5 Global T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 6 North America T-cell Lymphoma Market, by Country, 2018 - 2030 (USD Million)
Table 7 North America T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 8 North America T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 9 U.S. T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 10 U.S. T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 11 Canada T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 12 Canada T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 13 Mexico T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 14 Mexico T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 15 Europe T-cell Lymphoma Market, by Country, 2018 - 2030 (USD Million)
Table 16 Europe T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 17 Europe T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 18 Germany T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 19 Germany T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 20 UK T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 21 UK T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 22 France T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 23 France T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 24 Italy T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 25 Italy T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 26 Denmark T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 27 Denmark T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 28 Sweden T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 29 Sweden T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 30 Norway T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 31 Norway T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 32 Asia Pacific T-cell Lymphoma Market, by Country, 2018 - 2030 (USD Million)
Table 33 Asia Pacific T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 34 Asia Pacific T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 35 China T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 36 China T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 37 Japan T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 38 Japan T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 39 India T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 40 India T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 41 South Korea T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 42 South Korea T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 43 Australia T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 44 Australia T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 45 Thailand T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 46 Thailand T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 47 Latin America T-cell Lymphoma Market, by Country, 2018 - 2030 (USD Million)
Table 48 Latin America T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 49 Latin America T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 50 Brazil T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 51 Brazil T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 52 Argentina T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 53 Argentina T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 54 Middle East & Africa T-cell Lymphoma Market, by Country, 2018 - 2030 (USD Million)
Table 55 Middle East & Africa T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 56 Middle East & Africa T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 57 South Africa T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 58 South Africa T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 59 Saudi Arabia T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 60 Saudi Arabia T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 61 UAE T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 62 UAE T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 63 Kuwait T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
Table 64 Kuwait T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
Table 65 Financial performance
Table 66 Key companies undergoing expansions
Table 67 Key companies undergoing acquisitions
Table 68 Key companies undergoing collaborations
Table 69 Key companies launching new products/services
Table 70 Key companies undergoing partnerships
Table 71 Key companies undertaking other strategies

List of Figures
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 T-cell Lymphoma Market Segmentation
Fig. 7 Market Snapshot, 2023
Fig. 8 Market Trends & Outlook
Fig. 9 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 10 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 11 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 Global T-cell Lymphoma Market: By Type, Movement Analysis
Fig. 15 Global T-cell Lymphoma Market, for Peripheral, 2018 - 2030 (USD Million)
Fig. 16 Global T-cell Lymphoma Market, for Cutaneous T-cell Lymphoma, 2018 - 2030 (USD Million)
Fig. 17 Global T-cell Lymphoma Market, for Anaplastic Large Cell Lymphoma, 2018 - 2030 (USD Million)
Fig. 18 Global T-cell Lymphoma Market, for Angio-immuno-blastic T-cell Lymphoma, 2018 - 2030 (USD Million)
Fig. 19 Global T-cell Lymphoma Market, for Other, 2018 - 2030 (USD Million)
Fig. 20 Global T-cell Lymphoma Market, for Lymphoblastic, 2018 - 2030 (USD Million)
Fig. 21 Global T-cell Lymphoma Market: By Therapy, Movement Analysis
Fig. 22 Global T-cell Lymphoma Market, for Radiotherapy, 2018 - 2030 (USD Million)
Fig. 23 Global T-cell Lymphoma Market, for Chemotherapy, 2018 - 2030 (USD Million)
Fig. 24 Global T-cell Lymphoma Market, for Immunotherapy, 2018 - 2030 (USD Million)
Fig. 25 Global T-cell Lymphoma Market, for Stem Cell Transplantation, 2018 - 2030 (USD Million)
Fig. 26 Global T-cell Lymphoma Market, for Other, 2018 - 2030 (USD Million)
Fig. 27 Regional Marketplace: Key Takeaways T-cell Lymphoma Market,
Fig. 28 Regional Outlook, 2023 & 2030 T-cell Lymphoma Market,
Fig. 29 Global T-cell Lymphoma Market: Region Movement Analysis
Fig. 30 North America T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 31 U.S. T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 32 Canada T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 33 Mexico T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 34 Europe T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 35 Germany T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 36 UK T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 37 France T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 38 Italy T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 39 Spain T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 40 Denmark T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 41 Sweden T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 42 Norway T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 43 Asia Pacific T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 44 Japan T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 45 China T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 46 India T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 47 Australia T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 48 South Korea T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 49 Thailand T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 50 Latin America T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 51 Brazil T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 52 Argentina T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 53 Middle East and Africa T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 54 South Africa T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 55 Saudi Arabia T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 56 UAE T-cell Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 57 Kuwait T-cell Lymphoma Market, 2018 - 2030 (USD Million)